New cancer drug trial halted early – what we know
NCT ID NCT06171789
First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 2 times
Summary
This early-phase trial tested a new drug called PRO1107 in 33 people with advanced solid tumors, including ovarian, endometrial, breast, lung, and other cancers. The study aimed to check safety and see if the drug could shrink tumors. However, the trial was terminated early, so full results are not available.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PRO1107 (GEN1107)
What this could lead to
If successful, PRO1107 could offer a new treatment option for people with advanced solid tumors that have not responded to other therapies.
What could go wrong
This trial was terminated early, so results are limited. It is an early-phase study with a small number of participants, so safety and effectiveness are not yet established.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for OVARIAN CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Florida Cancer Specialists
Sarasota, Florida, 34236, United States
-
HonorHealth Research Institute
Scottsdale, Arizona, 85258, United States
-
Institution of Hunan Cancer Hospital
Changsha, Hunan, 410013, China
-
Massachusetts General Hospital
Boston, Massachusetts, 02114, United States
-
SCRI Oncology Partners
Nashville, Tennessee, 37203, United States
-
START Mountain Cancer Center
Salt Lake City, Utah, 78229, United States
-
The University of Texas MD Anderson Cancer Center
Houston, Texas, 77030, United States